Aflibercept is indicated for:
Population group: both men and women, only adults (18 years old or older)
Aflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Aflibercept is contraindicated in the following cases: